The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

The human miR-29 family of microRNAs has three mature members, miR-29a, miR-29b, and miR-29c. miR-29s are encoded by two gene clusters. Binding sites for several transcriptional factors have been identified in the promoter regions of miR-29 genes. The miR-29 family members share a common seed region sequence and are predicted to target largely overlapping sets of genes. However, the miR-29 family members exhibit differential regulation in several cases and different subcellular distribution, suggesting their functional relevance may not be identical. miR-29s directly target at least 16 extracellular matrix genes, providing a dramatic example of a single microRNA targeting a large group of functionally related genes. Strong antifibrotic effects of miR-29s have been demonstrated in heart, kidney, and other organs. miR-29s have also been shown to be proapoptotic and involved in the regulation of cell differentiation. It remains to be explored how various cellular effects of miR-29s determine functional relevance of miR-29s to specific diseases and how the miR-29 family members may function cooperatively or separately.

[1]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[2]  Akira Nakagawara,et al.  p53: The Attractive Tumor Suppressor in the Cancer Research Field , 2010, Journal of biomedicine & biotechnology.

[3]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[4]  Yong Liu,et al.  MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor β1: a novel role of miR-382 , 2010, Nucleic acids research.

[5]  V. Nguyen Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[6]  R. Turner,et al.  Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma , 2011, Epigenetics.

[7]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[8]  E. Lütjen-Drecoll,et al.  The effect of TGF-beta2 on elastin, type VI collagen, and components of the proteolytic degradation system in human optic nerve astrocytes. , 2008, Investigative ophthalmology & visual science.

[9]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[10]  H. Soifer,et al.  MicroRNAs in disease and potential therapeutic applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Jacob,et al.  Dynamic convergence and divergence of renal genomic and biological pathways in protection from Dahl salt-sensitive hypertension. , 2010, Physiological genomics.

[12]  S. Cohen,et al.  microRNA functions. , 2007, Annual review of cell and developmental biology.

[13]  S. Antonarakis,et al.  Regulation of fibrinogen production by microRNAs. , 2010, Blood.

[14]  Allen W. Cowley,et al.  Renal Medullary MicroRNAs in Dahl Salt-Sensitive Rats: miR-29b Regulates Several Collagens and Related Genes , 2010, Hypertension.

[15]  Xiongfei Xu,et al.  The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ , 2011, Nature Immunology.

[16]  J P Rapp,et al.  Dahl salt-susceptible and salt-resistant rats. A review. , 1982, Hypertension.

[17]  R J Roman,et al.  Genetically defined risk of salt sensitivity in an intercross of Brown Norway and Dahl S rats. , 2000, Physiological genomics.

[18]  Arturo Sala,et al.  B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. , 2005, European journal of cancer.

[19]  H. Haller,et al.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease , 2011, Nature Reviews Nephrology.

[20]  T. Pabst,et al.  The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML , 2010, British Journal of Cancer.

[21]  Yong Zhao,et al.  A developmental view of microRNA function. , 2007, Trends in biochemical sciences.

[22]  Carlo M. Croce,et al.  Biological Functions of miR-29b Contribute to Positive Regulation of Osteoblast Differentiation* , 2009, The Journal of Biological Chemistry.

[23]  Mingyu Liang,et al.  Molecular networks in Dahl salt-sensitive hypertension based on transcriptome analysis of a panel of consomic rats. , 2008, Physiological genomics.

[24]  A. Cowley The genetic dissection of essential hypertension , 2006, Nature Reviews Genetics.

[25]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[26]  Tint Lwin,et al.  microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.

[27]  R J Roman,et al.  Brown Norway Chromosome 13 Confers Protection From High Salt to Consomic Dahl S Rat , 2001, Hypertension.

[28]  Cheuk-Man Yu,et al.  TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. , 2011, Journal of the American Society of Nephrology : JASN.

[29]  R. Watson,et al.  Cell cycle regulation by the B-Myb transcription factor , 2003, Cellular and Molecular Life Sciences CMLS.

[30]  Z. Jing,et al.  A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to thoracic aortic dissection pathogenesis. , 2011, Journal of vascular surgery.

[31]  Torsten Haferlach,et al.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin , 2008, Proceedings of the National Academy of Sciences.

[32]  R. D'Agostino,et al.  Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population , 2000, Circulation.

[33]  H Tunstall-Pedoe,et al.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. , 2005, JAMA.

[34]  J. Qian,et al.  miR-29 is a major regulator of genes associated with pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[35]  Oliver Distler,et al.  MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.

[36]  S. Silbiger,et al.  Serum-stimulated α1 type IV collagen gene transcription is mediated by TGF-β and inhibited by estradiol. , 1998, American journal of physiology. Renal physiology.

[37]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[38]  G. Gronowicz,et al.  miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop* , 2010, The Journal of Biological Chemistry.

[39]  Thomas Manke,et al.  MicroRNAs Differentially Expressed in Postnatal Aortic Development Downregulate Elastin via 3′ UTR and Coding-Sequence Binding Sites , 2011, PloS one.

[40]  W. Meyer,et al.  Comparison of aldosterone binding in aortic cells from Dahl salt-susceptible and salt-resistant rats. , 1985, Life sciences.

[41]  Z. Galis,et al.  Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[42]  C. Croce,et al.  MicroRNA 29b functions in acute myeloid leukemia. , 2009, Blood.

[43]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[44]  H. Lan,et al.  Transforming growth factor-β and Smads. , 2011, Contributions to nephrology.

[45]  Jinqiao Qian,et al.  The role of microRNA in modulating myocardial ischemia-reperfusion injury. , 2011, Physiological genomics.

[46]  K. Pandit,et al.  MicroRNAs in idiopathic pulmonary fibrosis. , 2011, Translational research : the journal of laboratory and clinical medicine.

[47]  D. Epstein,et al.  Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells. , 2011, Investigative ophthalmology & visual science.

[48]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[49]  Y. Pekarsky,et al.  Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression , 2010, Proceedings of the National Academy of Sciences.

[50]  Brian S. Roberts,et al.  The colorectal microRNAome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[51]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[52]  P. Kantharidis,et al.  TGF-β Regulates miR-206 and miR-29 to Control Myogenic Differentiation through Regulation of HDAC4 , 2011, The Journal of Biological Chemistry.

[53]  S. Bronk,et al.  Transcriptional suppression of mir‐29b‐1/mir‐29a promoter by c‐Myc, hedgehog, and NF‐kappaB , 2010, Journal of cellular biochemistry.

[54]  S. Kumar,et al.  Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. , 1996, Journal of molecular and cellular cardiology.

[55]  Jin-Wu Nam,et al.  miR-29 miRNAs activate p53 by targeting p85α and CDC42 , 2009, Nature Structural &Molecular Biology.

[56]  J. S. Janicki,et al.  Contribution of ventricular remodeling to pathogenesis of heart failure in rats. , 2001, American journal of physiology. Heart and circulatory physiology.

[57]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[58]  Mingyu Liang,et al.  MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. , 2008, Genome research.

[59]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[60]  Hong Xu,et al.  MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. , 2009, Cancer research.

[61]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[62]  J. Long,et al.  MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic Nephropathy* , 2011, The Journal of Biological Chemistry.

[63]  E. Olson,et al.  Pervasive roles of microRNAs in cardiovascular biology , 2011, Nature.

[64]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[65]  M. Oren,et al.  p53: Guardian of ploidy , 2011, Molecular oncology.

[66]  C M Croce,et al.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Paul Ahlquist,et al.  MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins , 2008, Proceedings of the National Academy of Sciences.

[68]  Zhaoyong Hu,et al.  Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. , 2010, Cardiovascular research.

[69]  K. Bhatt,et al.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. , 2011, American journal of physiology. Renal physiology.

[70]  Y. Liu,et al.  MicroRNA: a new frontier in kidney and blood pressure research. , 2009, American journal of physiology. Renal physiology.

[71]  D. Ma,et al.  Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV‐related target genes for miR‐29 , 2011, The Journal of pathology.

[72]  Hui Zhou,et al.  High glucose down‐regulates miR‐29a to increase collagen IV production in HK‐2 cells , 2010, FEBS letters.

[73]  K. Yoshizato,et al.  Suppression of hepatic stellate cell activation by microRNA-29b. , 2011, Biochemical and biophysical research communications.

[74]  Y. Pekarsky,et al.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.

[75]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[76]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[77]  J. Hernandez,et al.  Comments on nomenclature of TOM genes/proteins and characterization of psi4Tom20, a novel processed pseudogene of the human Tom20 gene. , 2000, Genomics.

[78]  Mingyu Liang MicroRNA: a new entrance to the broad paradigm of systems molecular medicine. , 2009, Physiological genomics.

[79]  C. Coffill,et al.  The role of mutant p53 in human cancer , 2011, The Journal of pathology.

[80]  Shuang Huang,et al.  Uracils at nucleotide position 9–11 are required for the rapid turnover of miR-29 family , 2011, Nucleic acids research.

[81]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[82]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[83]  Hui Zhou,et al.  Deep Sequencing of Human Nuclear and Cytoplasmic Small RNAs Reveals an Unexpectedly Complex Subcellular Distribution of miRNAs and tRNA 3′ Trailers , 2010, PloS one.

[84]  Huating Wang,et al.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. , 2008, Cancer cell.

[85]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[86]  M. Olivier,et al.  Insights into Dahl salt-sensitive hypertension revealed by temporal patterns of renal medullary gene expression. , 2003, Physiological genomics.

[87]  M. Irigoyen,et al.  MicroRNAs 29 are involved in the improvement of ventricular compliance promoted by aerobic exercise training in rats. , 2011, Physiological genomics.

[88]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[89]  Mitsuo Kato,et al.  MicroRNAs and their role in progressive kidney diseases. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[90]  M. Vinciguerra,et al.  MicroRNA-29 in Aortic Dilation: Implications for Aneurysm Formation , 2011, Circulation research.

[91]  T. Luedde,et al.  Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis , 2011, Hepatology.

[92]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[93]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[94]  Kazufumi Suzuki,et al.  Recent Advances in p53 Research and Cancer Treatment , 2011, Journal of biomedicine & biotechnology.

[95]  J. Yun,et al.  Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.

[96]  J. Laine,et al.  The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.

[97]  Xiaopu Liu,et al.  Transforming growth factor-beta1 up-regulation of human alpha(1)(I) collagen is mediated by Sp1 and Smad2 transacting factors. , 2009, DNA and cell biology.

[98]  G. Gores,et al.  mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.

[99]  C. Croce,et al.  Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks* , 2009, The Journal of Biological Chemistry.

[100]  S. Gammeltoft,et al.  Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes , 2011, British journal of pharmacology.

[101]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[102]  Y. Pekarsky,et al.  Is miR-29 an oncogene or tumor suppressor in CLL? , 2010, Oncotarget.

[103]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[104]  D. Bluemke,et al.  Fibrinogen and left ventricular myocardial systolic function: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2010, American heart journal.

[105]  E. Wentzel,et al.  A Hexanucleotide Element Directs MicroRNA Nuclear Import , 2007, Science.

[106]  J. Foster,et al.  Activation of elastin transcription by transforming growth factor-beta in human lung fibroblasts. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[107]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.